Ying Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ying Zhang has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Bin Feng
Department of Biomedical Engineering, University of Connecticut, Storrs, CT, USA
1 shared publication - Chao Jiang
Key Laboratory of Standardization and Measurement for Nanotechnology, National Centre for Nanoscience and Technology 3 , Beijing 100029
1 shared publication - Ding Zhang
School of Materials Science and Engineering Nankai University Tianjin China
1 shared publication Fang Ning
Department of Psychiatry, The Second Clinical Medical College Zhejiang University of Traditional Chinese Medicine Hangzhou China
1 shared publication- Ge Nan
Department of Psychiatry, The Second Clinical Medical College Zhejiang University of Traditional Chinese Medicine Hangzhou China
1 shared publication - Hua-Ning Wang
Department of Psychiatry, Xijing Hospital, Fourth Military Medical University, Xi’an, China
1 shared publication
Latest Publications
- 8 August 2024
- Published by Elsevier in Electrochimica Acta
- Vol. 502
ZIF-8 nanoparticles densely covered MXene as functionalized platform for electrochemical detection of medical small molecules
- 8 August 2024
- Published by Elsevier in Electrochimica Acta
- Vol. 502
ZIF-8 nanoparticles densely covered MXene as functionalized platform for electrochemical detection of medical small molecules
- Open Access
- 19 December 2018
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 73 (4) , 179-186
Transcutaneous electrical acupoint stimulation for post‐traumatic stress disorder: Assessor‐blinded, randomized controlled study
Aim: Transcutaneous electrical acupoint stimulation (TEAS) has the potential to alleviate post‐traumatic stress disorder (PTSD). The purpose of this study was to determine whether adding TEAS to sertraline or cognitive behavioral therapy (CBT) could improve the anti‐PTSD efficacy.Methods: In this randomized controlled trial, 240 PTSD patients (60 in each group) were assigned to receive simulated TEAS combined with sertraline (group A) or with CBT (group B), active TEAS combined with CBT (group C), or active TEAS combined with CBT plus sertraline (group D) for 12 weeks. The outcomes were measured using the Clinician‐Administered PTSD Scale, PTSD Check List‐Civilian Version, and 17‐item Hamilton Rating Scale for Depression.Results: While PTSD symptoms reduced over time in all patients, groups C and D had markedly greater improvement in both PTSD and depressive measures than groups A and B in all post‐baseline measurement points, with moderate to very large effect sizes of 0.484–2.244. Groups C and D also had a significantly higher rate than groups A and B on clinical response (85.0% and 95.0% vs 63.3% and 60.0%, P < 0.001) and on remission (15.0% and 25.0% vs 3.3% and 1.7%, P < 0.001). The incidence of adverse events was similar between groups A and D and between groups B and C.Conclusions: Additional TEAS augments the anti‐PTSD and antidepressant efficacy of antidepressants or CBT, without increasing the incidence of adverse effects. TEAS could serve as an effective intervention for PTSD and comorbid depression. This trial was registered with www.chictr.org (no.: ChiCTR1800017255).
- 19 December 2018
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 73 (4) , 179-186
Open AccessTranscutaneous electrical acupoint stimulation for post‐traumatic stress disorder: Assessor‐blinded, randomized controlled study
Aim: Transcutaneous electrical acupoint stimulation (TEAS) has the potential to alleviate post‐traumatic stress disorder (PTSD). The purpose of this study was to determine whether adding TEAS to sertraline or cognitive behavioral therapy (CBT) could improve the anti‐PTSD efficacy.Methods: In this randomized controlled trial, 240 PTSD patients (60 in each group) were assigned to receive simulated TEAS combined with sertraline (group A) or with CBT (group B), active TEAS combined with CBT (group C), or active TEAS combined with CBT plus sertraline (group D) for 12 weeks. The outcomes were measured using the Clinician‐Administered PTSD Scale, PTSD Check List‐Civilian Version, and 17‐item Hamilton Rating Scale for Depression.Results: While PTSD symptoms reduced over time in all patients, groups C and D had markedly greater improvement in both PTSD and depressive measures than groups A and B in all post‐baseline measurement points, with moderate to very large effect sizes of 0.484–2.244. Groups C and D also had a significantly higher rate than groups A and B on clinical response (85.0% and 95.0% vs 63.3% and 60.0%, P < 0.001) and on remission (15.0% and 25.0% vs 3.3% and 1.7%, P < 0.001). The incidence of adverse events was similar between groups A and D and between groups B and C.Conclusions: Additional TEAS augments the anti‐PTSD and antidepressant efficacy of antidepressants or CBT, without increasing the incidence of adverse effects. TEAS could serve as an effective intervention for PTSD and comorbid depression. This trial was registered with www.chictr.org (no.: ChiCTR1800017255).
- Open Access
- 8 November 2017
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 15 (1) , 1005-1012
Magnesium isoglycyrrhizinate ameliorates doxorubicin‑induced acute cardiac and hepatic toxicity via anti‑oxidant and anti‑apoptotic mechanisms in mice
The present study investigated the effects and potential mechanisms of action of magnesium isoglycyrrhizinate (MgIG) in doxorubicin (DOX)‑treated mice. Histopathological analysis and western blot analysis were conducted in the liver and heart tissues and biochemical analysis of the serum was performed. The results revealed that MgIG (10, 20 and 40 mg/kg/day) could protect the structure and functions of the liver and heart by inhibiting the activities of the myocardial enzymes creatine kinase (CK), CK‑MB and lactate dehydrogenase and the hepatic‑specific enzymes aspirate aminotransferase and alanine aminotransferase, increasing the activities of the antioxidants superoxide dismutase and glutathione peroxidase, and inhibiting cellular apoptosis induced by DOX (30 mg/kg). These results demonstrate that inhibiting lipid peroxidation and reducing myocardial and hepatocyte apoptosis may be one of the mechanisms by which MgIG exhibits hepatoprotective and cardioprotective effects in DOX‑treated mice.
- 8 November 2017
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 15 (1) , 1005-1012
Open AccessMagnesium isoglycyrrhizinate ameliorates doxorubicin‑induced acute cardiac and hepatic toxicity via anti‑oxidant and anti‑apoptotic mechanisms in mice
The present study investigated the effects and potential mechanisms of action of magnesium isoglycyrrhizinate (MgIG) in doxorubicin (DOX)‑treated mice. Histopathological analysis and western blot analysis were conducted in the liver and heart tissues and biochemical analysis of the serum was performed. The results revealed that MgIG (10, 20 and 40 mg/kg/day) could protect the structure and functions of the liver and heart by inhibiting the activities of the myocardial enzymes creatine kinase (CK), CK‑MB and lactate dehydrogenase and the hepatic‑specific enzymes aspirate aminotransferase and alanine aminotransferase, increasing the activities of the antioxidants superoxide dismutase and glutathione peroxidase, and inhibiting cellular apoptosis induced by DOX (30 mg/kg). These results demonstrate that inhibiting lipid peroxidation and reducing myocardial and hepatocyte apoptosis may be one of the mechanisms by which MgIG exhibits hepatoprotective and cardioprotective effects in DOX‑treated mice.